<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03344861</url>
  </required_header>
  <id_info>
    <org_study_id>CLI-PHO1701</org_study_id>
    <nct_id>NCT03344861</nct_id>
  </id_info>
  <brief_title>Safety of PDT-Photofrin® Prior to Lung Surgery</brief_title>
  <official_title>A Multicenter, Prospective, Open-label, Non-randomized Single-arm Clinical Study of the Safety and Tissue Response to Photodynamic Therapy Using Porfimer Sodium for Injection as Treatment for Solid Lung Tumor Prior to Surgical Resection</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Concordia Laboratories Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Concordia Laboratories Inc.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
    <is_unapproved_device>No</is_unapproved_device>
    <is_ppsd>No</is_ppsd>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      This research study is being conducted to assess the safety of PDT in subjects with
      peripherally located malignant tumors in lung parenchyma prior to surgical resection. It will
      involve up to 10 sites in USA. Participation will last 4 months.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Lung cancer accounts for almost one-third of cancer deaths. Cancer screening strategies have
      the potential to achieve a 20% reduction in death rates. Newly developed bronchoscopic
      technologies (such as navigational bronchoscopy) have been shown to enable physicians to
      safely reach lesions in peripheral regions of the lung and obtain diagnosis. This new
      technology may now potentially offer bronchoscopic therapeutic interventions, such as
      photodynamic therapy, to tumors that were previously unreachable due to their peripheral
      anatomic location.

      Photodynamic therapy (PDT) uses a combination of a photosensitizing drug (a drug that is
      activated by light), called porfimer sodium (Photofrin®), and a light from a laser that emits
      no heat. This technique works to allow the medical doctor to specifically target and destroy
      abnormal or cancer cells while limiting damage to surrounding healthy tissue. The activation
      of the drug is done by lightning the abnormal area using a fiber optic device (very fine
      fiber [like a fishing line] that permits light transmission) inserted into a flexible tube
      with a light, called bronchoscope for the lung. The light activates the porfimer sodium
      concentrated in the abnormal tissue, leading to its destruction.

      The purpose of this study is to assess the safety of using photodynamic therapy prior to
      surgical resection of tumors located in the periphery of the lung.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">August 14, 2017</start_date>
  <completion_date type="Anticipated">November 2018</completion_date>
  <primary_completion_date type="Anticipated">June 2018</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Proportion of patients with serious and non-serious adverse events</measure>
    <time_frame>Up to 6 months</time_frame>
    <description>Safety evaluation will include incidence of adverse events.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Histological tissue response</measure>
    <time_frame>Day 13</time_frame>
    <description>Macroscopic and microscopic examinations will be tabulated and summarized for tumor tissue and healthy tissue</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">10</enrollment>
  <condition>Lung Cancer</condition>
  <condition>Lung Cancer Metastatic</condition>
  <arm_group>
    <arm_group_label>Photodynamic therapy-Photofrin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Photodynamic therapy (PDT) involves the i.v. injection of porfimer sodium (Photofrin®) followed by illumination of the tumor using a fiber optic device during navigational bronchoscopy. Two days after the injection, the laser light will be applied to the tumor.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Porfimer Sodium</intervention_name>
    <description>Porfimer sodium (Photofrin®) will be injected intravenously at a dose of 2 mg/kg.</description>
    <arm_group_label>Photodynamic therapy-Photofrin</arm_group_label>
    <other_name>Photofrin</other_name>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Fiber optic</intervention_name>
    <description>After injection of porfimer sodium (Photofrin®), a flexible bronchoscopy with navigation guidance will be performed to confirm the location and the size of the lesion with the use of radial probe endobronchial ultrasonography (REBUS). An optical fiber diffuser length matching the tumor length will be placed in the lesion or adjacent to the lesion under fluoroscopy guidance. After the placement of the optical fiber, the laser light will be applied at a dose of 200 J/cm of diffuser length.</description>
    <arm_group_label>Photodynamic therapy-Photofrin</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Male or female aged 18-79

          -  Diagnosed with primary or metastatic tumor &lt; 5 cm located in peripheral lung

          -  Candidate for surgical resection

          -  Candidate for bronchoscopy

        Exclusion Criteria:

          -  Diagnostic of small cell lung cancer or carcinoid tumors

          -  Primary or metastatic lung tumor located in central lung or near vertebral body

          -  Tumor invades a major blood vessel

          -  Presence of concurrent non-solid malignancy

          -  Tumor previously treated with radiation therapy

          -  Chemotherapy in the last four weeks

          -  Tumor treated with PDT within the last 3 months

          -  Abnormal blood results
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>79 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Erin O'Neil</last_name>
    <role>Study Chair</role>
    <affiliation>Concordia Laboratories Inc.</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Kim McDonald-Taylor, M.Sc.</last_name>
    <phone>647-267-2942</phone>
    <email>kmcdonald-taylor@rogers.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Michelle Depot, Ph.D.</last_name>
    <phone>514-971-5591</phone>
    <email>michelle.depot@concordiarx.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Cedars-Sinai Medical Center</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90048</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jenny Park, MPH</last_name>
      <phone>310-423-8762</phone>
      <phone_ext>38762</phone_ext>
      <email>Jenny.Park@cshs.org</email>
    </contact>
    <investigator>
      <last_name>Harmik J Soukiasian, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Colorado</name>
      <address>
        <city>Denver</city>
        <state>Colorado</state>
        <zip>80045</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Paula Fisk</last_name>
      <phone>720-848-0676</phone>
      <email>paula.fisk@ucdenver.edu</email>
    </contact>
    <investigator>
      <last_name>Ali I Musani, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Moffitt Cancer Center</name>
      <address>
        <city>Tampa</city>
        <state>Florida</state>
        <zip>33612</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Vonny Ortega</last_name>
      <phone>813-745-4258</phone>
      <email>vonny.ortega@moffitt.org</email>
    </contact>
    <investigator>
      <last_name>Eric M Toloza, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Cancer Treatment Centers of America/Southeastern</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30265</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mittie Mitchell</last_name>
      <phone>770-400-7194</phone>
      <email>mittie.mitchell@ctca-hope.com</email>
    </contact>
    <investigator>
      <last_name>Rabih I Bechara, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>AMITA Health Alexian Brothers Medical Center</name>
      <address>
        <city>Elk Grove Village</city>
        <state>Illinois</state>
        <zip>60007</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>April Levesque, RN</last_name>
      <phone>847-385-7319</phone>
      <email>april.levesque@amitahealth.org</email>
    </contact>
    <investigator>
      <last_name>Neeraj R Desai, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Dubois Medical Center</name>
      <address>
        <city>DuBois</city>
        <state>Pennsylvania</state>
        <zip>15801</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Shari Edevane</last_name>
      <phone>814-940-1212</phone>
      <phone_ext>0314</phone_ext>
      <email>shari@clinicalresearchassoc.com</email>
    </contact>
    <investigator>
      <last_name>Sandeep Bansal, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>UT MD Anderson Cancer Center</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Laila Noor, MDMS</last_name>
      <phone>713-745-2645</phone>
      <email>lznoor@mdanderson.org</email>
    </contact>
    <investigator>
      <last_name>Roberto F Casal, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Providence Health &amp; Services</name>
      <address>
        <city>Spokane</city>
        <state>Washington</state>
        <zip>99204</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Tracy Roundy, BS,CCRP</last_name>
      <phone>509-474-3823</phone>
      <email>tracy.roundy@providence.org</email>
    </contact>
    <investigator>
      <last_name>Jiten D Patel, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 13, 2017</study_first_submitted>
  <study_first_submitted_qc>November 15, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">November 17, 2017</study_first_posted>
  <last_update_submitted>May 15, 2018</last_update_submitted>
  <last_update_submitted_qc>May 15, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">May 16, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>lung cancer</keyword>
  <keyword>lung carcinoma</keyword>
  <keyword>lung metastases</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lung Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dihematoporphyrin Ether</mesh_term>
    <mesh_term>Hematoporphyrin Derivative</mesh_term>
    <mesh_term>Trioxsalen</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

